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STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted
therapy for the treatment of a specific cancer.This article reviews the identification of Bcr-Abl as a therapeutic target in chron-
ic myelogenous leukemia and the steps in the development of an agent to specifically inactivate this abnormality. Issues relat-
ed to clinical trials of molecularly targeted agents are discussed, including dose and patient selection, as are possible mech-
anisms of resistance to STI571. Lastly, the potential use of STI571 in other malignancies and the translation of this paradigm
to other malignancies is explored.
The introduction of STI571, an agent targeted against the
causative molecular event in chronic myeloid leukemia (CML),
has been heralded as a major advance in the treatment of can-
cer (Chabner, 2001; Von Hoff and Bootman, 2001). STI571
owes much to the rich history of scientific discovery in CML
beginning with the description of the Philadelphia chromosome
in 1960 (Nowell and Hungerford, 1960). Many of the scientific
discoveries in CML were firsts in cancer research, while others
paralleled the state of the art in cancer research (Druker, 2001;
Mauro et al., 2002; Rowley, 2001). Thus, STI571 has validated
nearly four decades of cancer research into the molecular etiol-
ogy of cancer and has substantiated the concept that a precise
understanding of the pathogenesis of a cancer can lead to
effective therapies. This article will provide an overview of the
development of STI571 along with the lessons learned in the
clinical trials of this molecular pathogenetically targeted agent.
Chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem
cell disorder. It accounts for 15%–20% of all cases of leukemia
with an annual incidence of 1 to 2 cases per 100,000 per year.
The median age at diagnosis is between 50 and 60 years of
age. Clinically, the disease progresses through distinct phases
referred to as chronic, accelerated, and blast. The chronic or
stable phase of the disease is characterized by excess numbers
of myeloid cells that differentiate normally.Within an average of
4–6 years, the disease transforms through an “accelerated
phase” to an invariably fatal acute leukemia, also known as blast
crisis. Disease progression is likely due to the accumulation of
molecular abnormalities that lead to a progressive loss of the
capacity for terminal differentiation of the leukemic clone
(Faderl et al., 1999; Sawyers, 1999). The accelerated and blast
phases of the disease are highly refractory to therapy.
Response rates to standard chemotherapy in myeloid blast cri-
sis are 20% or less and the median survival is 2–3 months
(Faderl et al., 1999; Sacchi et al., 1999; Sawyers, 1999).
Bcr-Abl as a therapeutic target in CML
The hallmark of CML is the Philadelphia chromosome. First
identified in 1960 as a shortened chromosome in marrows of
CML patients, it was subsequently shown to result from a recip-
rocal translocation between chromosomes 9 and 22 (Nowell
and Hungerford, 1960; Rowley, 1973). The molecular conse-
quence of this translocation is the replacement of the first exon
of c-abl with sequences from the bcr gene resulting in a bcr-abl
fusion gene and mRNA (de Klein et al., 1982; Groffen et al.,
1984; Heisterkamp et al., 1983; Shtivelman et al., 1985). The
resulting Bcr-Abl fusion protein has enhanced tyrosine kinase
activity (Konopka et al., 1984). Bcr-Abl is present in 95% of
patients with CML. In a variety of animal models, Bcr-Abl, as the
sole oncogenic event, has been conclusively established as a
leukemic oncogene (Daley et al., 1990; Heisterkamp et al.,
1990; Huettner et al., 2000; Kelliher et al., 1990). Bcr-Abl func-
tions as a constitutively activated tyrosine kinase, and this
kinase activity leads to the pathological defects of CML. These
include increased proliferation, protection from programmed
cell death, and possibly genetic instability that leads to disease
progression (Deininger et al., 2000). However, all of the trans-
forming functions of the Bcr-Abl protein are dependent on the
tyrosine kinase activity of the Abl portion of this protein (Lugo et
al., 1990). Thus, an inhibitor of the Abl protein tyrosine kinase
would be predicted to be an effective and selective therapeutic
agent for CML.
STI571 as a therapeutic agent for CML
STI571 (formerly CGP 57148, now imatinib mesylate, Gleevec, or
Glivec) was synthesized in a kinase inhibitor program at Novartis,
with one of the targets being the platelet-derived growth factor
receptor (PDGF-R) tyrosine kinase. The most potent molecules
generated were inhibitors of the Abl and the PDGF-R-α and β
kinases (Buchdunger et al., 2001; Druker and Lydon, 2000).
STI571 emerged as the lead compound for clinical development
based on its superior in vitro selectivity against CML cells and its
drug-like properties, including pharmacokinetic and formulation
properties (Druker and Lydon, 2000). Extensive profiling of
STI571 has shown that the only other kinase inhibited by STI571
is the Kit tyrosine kinase (Druker and Lydon, 2000).
Preclinical studies showed that STI571 specifically inhibits
the proliferation of cells expressing Bcr-Abl in vitro and in vivo
(Deininger et al., 1997; Druker et al., 1996; Gambacorti-Passerini
et al., 1997). STI571 levels of 1 µM were optimal for cell killing in
vitro (Buchdunger et al., 2001). Studies in mice showed that con-
tinuous exposure to STI571 was necessary to eradicate the
tumors (Deininger et al., 1997; Druker et al., 1996; Gambacorti-
Passerini et al., 1997), suggesting this would be important for
optimal anti-leukemic effects. Prior to clinical testing, STI571 was
shown to have an acceptable animal toxicology profile.
Clinical studies of STI571
In Phase I clinical trials of STI571, 14 patient cohorts were treat-
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ed with escalating daily oral doses of STI571, ranging from 25 to
1000 mg (Druker et al., 2001b). In these studies, no dose-limit-
ing toxicities were observed. Once doses of 300 mg or greater
were reached, significant clinical benefits were observed. In
chronic phase patients who had failed standard therapy with
interferon, 53/54 patients achieved a complete hematologic
response, typically within 4 weeks of starting therapy. 51/53
patients maintained normal blood counts after one year of ther-
apy (Druker et al., 2001b). In myeloid blast crisis patients, 60%
of patients responded to therapy with STI571, but only 18% of
patients had responses lasting longer than one year (Druker et
al., 2001a).
The Phase I results were confirmed in rapidly accruing
Phase II studies (Kantarjian et al., 2001; Sawyers et al., 2001;
Talpaz et al., 2001). In 532 chronic phase patients who failed
interferon therapy, 95% of patients achieved a complete hema-
tologic response with STI571 at 400 mg per day. 60% of patients
had a reduction in the percentage of Philadelphia chromosome
positive metaphases to less than 35%, and 41% of patients
achieved a complete cytogenetic remission. With a median
duration of followup of 18 months, only 9% of patients have
relapsed (Kantarjian et al., 2001). In myeloid blast crisis, of 232
patients treated, 52% responded, but only 22% had responses
lasting longer than one year (Sawyers et al., 2001).
Toxicity from therapy has been relatively mild. Only 2% of
chronic phase patients discontinued therapy due to adverse
events (Kantarjian et al., 2001). The most common side effects
have been mild and include nausea, periorbital edema, muscle
cramps, and myelosuppression (Druker et al., 2001b). The rare
serious adverse events have included skin rashes, fluid reten-
tion, elevated liver function tests, and prolonged myelosuppres-
sion. The incidence of myelosuppression is much greater in
CML patients than in solid tumor patients (Blanke et al., 2001).
This suggests that myelosuppression is a therapeutic effect in
CML patients where hematopoiesis is predominantly con-
tributed by the Bcr-Abl positive clone.
Why was STI571 so successful?
There were several important elements to the success of
STI571, but perhaps none as important as the target itself, Bcr-
Abl. As noted above, Bcr-Abl is the causative molecular abnor-
mality of CML and early in the disease course may be the sole
oncogenic event. All of the transforming functions of Bcr-Abl are
dependent on its tyrosine kinase activity; thus an inhibitor of this
kinase would be predicted to be an effective therapeutic agent.
An equally as important issue is that the initial clinical trials
were limited to patients with Bcr-Abl positive CML. As STI571 is
an Abl inhibitor, it would make sense to try this agent in a dis-
ease that was known to be critically dependent on Abl kinase
activity. CML is ideal as 95% of patients are Bcr-Abl positive and
can be easily identified by the presence of the Ph chromosome,
by FISH analysis for Bcr-Abl rearrangements, or by RT-PCR for
Bcr-Abl transcripts. Thus, patients were selected for the clinical
trial based on the presence of an appropriate target for STI571.
Lastly, CML is a disease that exemplifies the concept of
multistage tumor progression. Early in the course of the dis-
ease, it is likely the Bcr-Abl is the sole molecular abnormality.
Over time, the leukemic clone accumulates additional molecular
changes as the disease progresses toward blast crisis. As seen
in the clinical trials, the response rate and durability of respons-
es is greater in chronic phase patients than patients with more
advanced disease. Even in blast crisis patients, Bcr-Abl remains
a good target as in the majority of patients, the malignant clone
remains at least partially dependent on Bcr-Abl kinase activity
for survival (Druker et al., 2001a). However, STI571 alone is
clearly insufficient for most blast crisis patients.
In reflecting on the success of STI571, it is clear that com-
bining a critical pathogenetic target that is easily identifiable
early in the course of the disease with an agent that targets this
abnormality led to the remarkable results observed in the clini-
cal trials of STI571. In this scenario, early stage CML may be
more akin to a carcinoma in situ. To recapitulate the success of
STI571 in other malignancies, it would be essential to identify
early pathogenetic changes. In parallel, it would be necessary
to develop extremely reliable techniques to identify patients with
early stage disease.
Why have side effects of STI571 been so minimal?
One of the surprising aspects of the clinical trials was how well
tolerated this therapy has been. Abl null animals are viable, but
have a variety of neurological defects, lymphopenia and typical-
ly die shortly after birth (Schwartzberg et al., 1991; Tybulewicz
et al., 1991). Animals lacking either the PDGF-R-α or β die in
early gestation with a variety of developmental defects, includ-
ing neural crest abnormalities (α) and renal, cardiovascular, and
hematological abnormalities (β) (Soriano, 1994, 1997).
Inactivating mutations of Kit results in embryonic lethality due to
severe anemia (Russell, 1979). These animals also have defi-
ciencies in melanocytes, germ cells, and mast cells (Dolci et al.,
1991). Based on these observations, it would seem likely that
significant side effects would be observed with STI571.
The lack of side effects of STI571 might be due to the lack of
a critical role for the kinases targeted by STI571 in an adult ani-
mal as opposed to their critical role during embryonic develop-
ment. Alternatively, humans may have redundant gene function
compared with mice that minimizes the effect of loss of these
kinases. Lastly, it is possible that residual kinase activity may
persist during STI571 therapy and this may be sufficient to pro-
tect dependent tissues. If this latter explanation is correct, then
side effects might become more apparent as more potent
kinase inhibitors are generated.
Why do cytogenetic responses occur?
Bcr-Abl functions either by enhancing the proliferation of a
hematopoietic progenitor or by protecting progenitors from pro-
grammed cell death (Deininger et al., 2000). In the former case,
it is possible that STI571 would simply prevent proliferation of
the leukemic clone without eliminating it. Even in this scenario, it
is possible that cytogenetic responses would be observed.
Presumably, with inhibition of Bcr-Abl kinase activity, the
leukemic clone would be subjected to normal marrow regulatory
influences and would be eliminated at the end of the progenitor
cell’s natural life span. It is also possible that normal hematopoi-
etic progenitors would regain a proliferative advantage or that
progression to blast crisis could be delayed or avoided. If Bcr-
Abl protects from apoptotic cell death, it is possible that treat-
ment with a kinase inhibitor could eliminate the leukemic clone.
However, cytogenetic responses are not seen in all
patients. The simplest explanation is that some patients have
additional molecular abnormalities in a clone of cells that medi-
ates resistance. Another possibility is that quiescent stem cells
may be insensitive to STI571 (Graham et al., 2001), suggesting
that complete eradication of the malignant cell with single agent
STI571 would be unlikely. Alternatively, different stages of
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hematopoietic stem cell development could be involved in the
initial pathogenesis of CML. If the stem cells have differential
sensitivity to STI571, this may explain the variability in cytoge-
netic responses.
Dose selection
In the Phase I clinical trials of STI571, a maximally tolerated
dose of STI571 was never reached (Druker et al., 2001b). Even
among those closely associated with the Phase I studies, there
was a lack of consensus about when to discontinue dose esca-
lation. There were some investigators who felt that no cap on
the dose should be considered except the maximally tolerated
dose, particularly since studies in solid tumors were planned
and since penetration of STI571 into solid tumors might require
higher doses. Others felt that alternate endpoints, such as opti-
mal therapeutic response and/or pharmacokinetic endpoints,
could be used. In evaluating pharmacokinetic endpoints, it was
known from preclinical studies that continuous exposure of cells
to STI571 doses of 1 µM or higher resulted in maximal cell
killing (Druker and Lydon, 2000). In the Phase I clinical trials, a
trough level of 1 µM was reached at a dose level of 300 mg,
which corresponds to a threshold for significant therapeutic
benefits (Peng et al., 2001). Thus, pharmacokinetic parameters
could have been used to predict therapeutic responses.
Similarly, an analysis of responses in blood counts over time
suggested that doses of 400 to 600 mg were on the plateau of a
dose-response curve (Peng et al., 2001). Thus, an analysis of
optimal therapeutic responses led to a similar conclusion that
doses greater than 300 mg should be chosen for Phase II trials.
However, the analysis of optimal therapeutic responses may not
always be available from early clinical trials, particularly since
disease-free survival may be the best parameter to measure.
When using molecularly targeted agents, it would seem
more reasonable to consider maximal modulation of the target
as the therapeutic endpoint. In the case of CML and a Bcr-Abl
inhibitor, the obvious choice would be to assess for maximal
inhibition of Bcr-Abl kinase activity. An analysis of Bcr-Abl
kinase inhibition, performed by assaying for decreases in phos-
phorylation of the Bcr-Abl substrate, Crkl, have shown that a
plateau in inhibition is seen above 250 mg (Druker et al.,
2001b). Additional experiments are being conducted to deter-
mine the percentage of Bcr-Abl kinase activity that is being
inhibited at these dose levels. Once again, there are advan-
tages in CML in that the tumor cells are easily accessible and
that the kinase itself or its substrates could be monitored for
inhibition.These types of assays will clearly be more problemat-
ic for solid tumors but will likely be necessary to determine the
penetration of agent into the tumor. In the absence of specific
assays, information about intracellular drug levels in tumor sam-
ples would also be a useful surrogate.This type of data, regard-
ing maximal kinase inhibition, could be particularly useful in
explaining response variability, determining mechanisms of
relapse, and individualizing patient dosing.
Mechanisms of relapse/resistance to STI571
Resistance to STI571 includes de novo resistance and relapse
after an initial response. One of the most useful categorizations
of relapse/resistance mechanisms has been separation of
patients with persistent inhibition of the Bcr-Abl kinase and
those with reactivation of the Bcr-Abl kinase (Figure 1). Patients
with persistent inhibition of the Bcr-Abl kinase would be predict-
ed to have additional molecular abnormalities besides Bcr-Abl
driving the growth and survival of the malignant clone. In con-
trast, patients with persistent Bcr-Abl kinase activity or reactiva-
tion of the kinase would be postulated to have resistance mech-
anisms that either prevent STI571 from reaching the target or
render the target insensitive to Bcr-Abl. In the former category
are mechanisms such as drug efflux or protein binding of
STI571. In the latter category would be mutations of the Bcr-Abl
kinase that render Bcr-Abl insensitive to STI571 and amplifica-
tion of the Bcr-Abl protein.
In patients who relapse after an initial response to STI571,
the majority of patients have reactivation of the Bcr-Abl kinase
(Gorre et al., 2001). No changes in drugs levels have been
observed, and leukemic cells from these patients have
decreased cellular sensitivity to STI571 (Gorre et al., 2001).
This suggests that resistance is due to intrinsic cellular proper-
ties rather than protein binding of drug or drug metabolism.
Interestingly, half of these patients have developed point muta-
tions in the Abl kinase that render the kinase variably less sensi-
tive to STI571 (Branford et al., 2001; Hochhaus et al., 2001;
Shah et al., 2001). Two of the point mutations are at sites pre-
dicted to be contact sites between STI571 and the Abl kinase
based on the crystal structure (Gorre et al., 2001; Barthe et al.,
2001; Branford et al., 2001; Hochhaus et al., 2001; Schindler et
al., 2000) (Figure 2). Some are at residues adjacent to contact
points, while others are in the kinase activation loop (Barthe et
al., 2001; Branford et al., 2001; Hochhaus et al., 2001; Shah et
al., 2001). Lastly, approximately one-third of patients who
relapse after an initial response have Bcr-Abl amplification
(Hochhaus et al., 2001). In these patients, Bcr-Abl remains a
good target for therapy, and inhibitors with activity against the
Abl mutations or more potent Abl inhibitors will be required. Bcr-
Abl mutation and amplification have not been commonly seen in
patients with de novo STI571 resistance, and ongoing studies
are aimed at identifying mechanisms of resistance in these
patients.
Optimizing therapy with STI571
One of the tasks for the future will be to predict response pat-
terns of patients. This will include predictions based on individ-
ual genetic factors that might influence parameters, such as
drug metabolism as well as the genetic makeup of the tumor.
Current techniques to predict responses use pretreatment clini-
cal features that are likely surrogate markers for specific genet-
Figure 1. Distinguishing between potential mechanisms of relapse
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ic alterations in tumors (Goldman and Druker, 2001).Microarray
techniques that survey the gene expression pattern of tumors
have already been demonstrated to distinguish subgroups with
different clinical outcomes from a larger group of apparently
clinically homogenous patients (Alizadeh et al., 2000; Shipp et
al., 2000). Thus, the ideal situation would be to predict specific
response patterns of patients prior to treatment and treat
patients with the minimally toxic, but effective, therapy. In the
meantime, STI571 will be combined with standard anti-leukemic
agents to increase cytogenetic and molecular response rates in
chronic phase patients and to increase durability of responses
in advanced phase patients. In the future, additional rational tar-
gets for therapy will be identified from studies of molecular
mechanisms of resistance.
Translating the success of STI571 to other malignancies
STI571 specifically inhibits the Abl, PDGF-R, and c-kit tyrosine
kinases, but no other kinase tested. Initial clinical trials targeted
patients with CML where Bcr-Abl tyrosine kinase activity was
known to be a pathogenetic event. Shortly thereafter, clinical tri-
als were initiated in GIST patients, where activating mutations
of c-kit are a pathogenetic event (Heinrich et al., 2002). Again,
remarkable clinical activity was seen in this previously
chemotherapy refractory tumor (Blanke et al., 2001; van
Oosterom et al., 2001). One of the most interesting findings in
the GIST clinical trials is that the response rate to STI571 is sig-
nificantly higher in patients with mutated/activated c-kit as
opposed to patients who express the wild-type, nonmutated
c-kit (Blanke et al., 2001). These data demonstrate a critically
important concept, that expression does not necessarily equate
with pathogenesis.
Kit is expressed in a variety of tumors, including acute
myeloid leukemia, small cell lung carcinoma, germ cell tumors,
melanoma, myeloma, and neuroblastoma (Heinrich et al.,
2002). Whether c-kit contributes to the pathogenesis of these
diseases is not clear. It is possible that c-kit tyrosine kinase
activity is required for survival of these tumors; however, clinical
trials in these disorders will be required to determine the activity
of STI571 in these diseases.The Tel-PDGF-R fusion, seen as a
consequence of the (5;12) translocation in a subset of chronic
myelomonocytic leukemia patients, is a well-validated patho-
genetic target, and STI571 has shown remarkable activity in
patients with this disease (Apperley et al., 2001; Carroll et al.,
1997; Golub et al., 1994). Glioblastomas have a reasonably
well-described autocrine activation of the PDGF-R; however,
the complexity of these tumors may obscure clinical activity.
Despite the presence of the PDGF-R on many other common
tumors, the precise contribution of this receptor to the growth
and survival of these tumors is not clear. Again, clinical trials of
STI571 have been initiated and may define the contribution of
this pathway. In the absence of clear validation of the PDGF-R
or c-kit, predictions regarding activity in these tumors would be
premature. Thus, despite the fact that a molecular targeted
agent is being used, we still are left resorting to empiricism to
define clinical activity.
Concluding thoughts
As much cause as there is for celebration of the success of
STI571, it is worth remembering that the success of STI571
was based in large part on the fact that it targeted the most well
validated target in all of oncology.To recapitulate the success of
STI571 in other malignancies, it would be essential to identify
early pathogenetic changes in all cancers and to develop reli-
able means to identify patients with these abnormalities. But
how many pathogenetic events will characterize each cancer?
Will there be few or will there be many? It is also worth remem-
bering that drugs that target pathways that are not pathogenetic
events may also be good targets.The best examples are tamox-
ifen in breast cancer and the anti-androgenic agents in prostate
cancer. Mutations or constitutive activation of the estrogen or
androgen receptors are not known to be pathogenetic events in
breast or prostate cancer, yet the activity of these receptors is
critical to the survival of these tumors. Thus, targeting these
receptors has been an extremely useful therapeutic approach in
these malignancies. This demonstrates that any pathway that is
critical to the development, growth, or survival of a cancer could
be a useful therapeutic target. Our task is to define these appro-
priate targets in each cancer and to develop agents that reverse
the abnormal function of these proteins. As easy as STI571
made it look, there is still much work to be done.
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Figure 2. Crystal structure of Abl bound to an STI571-related compound
Dashed lines indicate hydrogen bonding. Curved lines indicate van der
Waals interactions. Residues marked with an asterisk are contact points
where mutations have been identified in patients with clinical resistance to
STI571. Double asterisks are at contact points where mutation of an adja-
cent residues has been associated with resistance. Reprinted with permis-
sion from Schindler et al. (2000).
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